ELTX - Company ID 0001601485
The table below shows Elicio Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$36.95M | -$37.07M | -$32.69M | -$22.18M | -$52.64M | -$22.89M |
| Capital expenditure | $16.00K | $87.00K | $66.00K | $654.00K | $382.00K | $41.00K |
| Investing cash flow | -$16.00K | -$84.00K | -$32.00K | -$654.00K | -$382.00K | -$41.00K |
| Dividends paid | - | - | - |
Elicio Therapeutics, Inc. reported operating cash flow of -$36.95M for fiscal year 2025. That is up 0.3% from -$37.07M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$22.89M (FY 2020) to -$36.95M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $36.70M | $42.32M | $38.61M | $21.20M | $107.17M | $52.41M |